{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-2.4","upperLimit":"12.3","value":"4.9"},{"groupId":"OG001","lowerLimit":"-6.2","upperLimit":"7.5","value":"0.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"title":"Fatigue at Day 64"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-3.7","upperLimit":"14.1","value":"5.2"},{"groupId":"OG001","lowerLimit":"-8.8","upperLimit":"7.7","value":"-0.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"title":"Fatigue at Day 134"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-9.2","upperLimit":"2.3","value":"-3.4"},{"groupId":"OG001","lowerLimit":"-5.6","upperLimit":"5.2","value":"-0.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"title":"Physical Functioning at Day 64"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-10.2","upperLimit":"3.2","value":"-3.5"},{"groupId":"OG001","lowerLimit":"-6.0","upperLimit":"6.4","value":"0.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"title":"Physical Functioning at Day 134"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-4.0","upperLimit":"9.0","value":"2.5"},{"groupId":"OG001","lowerLimit":"-5.0","upperLimit":"7.1","value":"1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"title":"Global Health Status at Day 64"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-6.2","upperLimit":"8.0","value":"0.9"},{"groupId":"OG001","lowerLimit":"-3.3","upperLimit":"9.5","value":"3.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"title":"Global Health Status at Day 134"}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"description":"EORTC QLQ-C30 is a 30 item questionnaire composed of 5 multi-item functional subscales (physical, role, cognitive, emotional, and social functioning), 3 multi-item symptom scales (fatigue, nausea/vomiting, and pain), a global health/quality of life (QOL) subscale, and 6 single items assessing other cancer related symptoms (dyspnea, sleep disturbance, appetite, diarrhea, constipation, and the financial impact of cancer). The questionnaire employed twenty-eight 4 point Likert scales with responses from \"not at all\" to \"very much\" and two 7 point Likert scales for global health and overall QOL. For functional and global QOL scales, higher scores represented a better level of functioning and all scores were converted to a 0 to 100 scale. For symptom oriented scales, a higher score represented more severe symptoms, and all scores were converted to a 0-100 scale. Negative changes from baseline indicate deterioration in functioning / global QoL scales and improvement in symptom scales.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 3 cycles of oral solution of Xevinapant at a dose of 200 milligrams per day (mg/day) once daily from Day 1 to 14, per 3-week cycle in combination with 66 Gray (Gy) of intensity modulated radiation therapy (IMRT) in 33 fractions, 2 Gy/fraction, 5 days/week followed by 3 cycles of monotherapy of Xevinapant at a dose of 200 mg/day from Day 1 to 14, per 3-week cycle (Each cycle is of 3 weeks).","id":"OG000","title":"Xevinapant +IMRT"},{"description":"Participants received 3 cycles of oral solution of placebo matched to Xevinapant once daily from Day 1 to 14 per 3-week cycle in combination with with 66 Gray (Gy) of intensity modulated radiation therapy (IMRT) in 33 fractions, 2 Gy/fraction, 5 days/week followed by 3 cycles of monotherapy of placebo matched to Xevinapant from Day 1 to 14, per 3-week cycle (Each cycle is of 3 weeks).","id":"OG001","title":"Placebo +IMRT"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"FAS included all participants who were randomized to study treatment. Here,\"Overall Number of Participants Analyzed\" signifies the participants who were evaluable for this outcome measure and \"number analysed\" signifies participants at the specific categories.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 64 and End of treatment (Day 134)","title":"Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) Score","type":"SECONDARY","unitOfMeasure":"score on a scale"}